---
title: "301301.SZ (301301.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301301.SZ/news.md"
symbol: "301301.SZ"
name: "301301.SZ"
parent: "https://longbridge.com/en/quote/301301.SZ.md"
datetime: "2026-03-14T21:15:42.439Z"
locales:
  - [en](https://longbridge.com/en/quote/301301.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301301.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301301.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/301301.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/301301.SZ/news.md)


# 301301.SZ (301301.SZ) — Related News

### [Yili Chuanning Bio: The main overseas sales locations for the company's products are regions such as India and Hong Kong](https://longbridge.com/en/news/277902426.md)
*2026-03-05T08:11:34.000Z*
> On March 5th, Yili Chuanning Bio stated on the interactive platform that the main overseas sales locations for the compa

### [600 million financing exhausted, over 1.1 billion spent on acquisitions, Dongning Bio's "burning money" expansion struggles to achieve profitability](https://longbridge.com/en/news/274835738.md)
*2026-02-04T15:05:08.000Z*
> 600 million financing exhausted, over 1.1 billion spent on mergers and acquisitions, Dongning Bio's "burning money" expa

### [Yili Chuanning Bio: Some fundraising projects have been completed, and the remaining funds of CNY 60.5513 million will be used for other purposes](https://longbridge.com/en/news/270708557.md)
*2025-12-24T09:09:43.000Z*
> Yili Chuanning Bio announced that it raised 1.022 billion yuan through its initial public offering, with some fundraisin

### [Yili Chuanning Bio: The controlling shareholder extends the lock-up period, with fundamentals supporting value anchoring](https://longbridge.com/en/news/269961907.md)
*2025-12-17T05:28:54.000Z*
> Yili Chuanning Bio announced that its controlling shareholder Sichuan Kelun Pharma and its controlled Chengdu Kelun Ning

### [Yili Chuanning Bio: The controlling shareholder has added a commitment to extend the share lock-up period until December 27, 2026](https://longbridge.com/en/news/269829911.md)
*2025-12-16T08:12:41.000Z*
> Yili Chuanning Bio announced that its controlling shareholder Kelun Pharmaceutical and its controlled Kelun Ninghui volu

### [Yili Chuanning Bio: Net profit in the third quarter was 157 million yuan, a year-on-year decrease of 49.44%](https://longbridge.com/en/news/262870652.md)
*2025-10-27T10:33:42.000Z*
> Yili Chuanning Bio announced that its revenue for the third quarter was 1.087 billion yuan, a year-on-year decrease of 1

### ["Trillion-level" biomanufacturing, how to "change lanes and overtake" to reshape the landscape of the pharmaceutical and other industries](https://longbridge.com/en/news/262774897.md)
*2025-10-26T12:24:12.000Z*
> Biomanufacturing is becoming a key force driving China's economic growth and sustainable development. The government has

### [Yili Chuanning Bio has been approved to register 1 billion yuan medium-term notes](https://longbridge.com/en/news/257024472.md)
*2025-09-12T03:54:05.000Z*
> According to the Zhitong Finance APP, Yili Chuanning Bio announced that the company has received the "Acceptance of Regi

### [KELUN PHARMA: With the arrival of the peak season in the fourth quarter, Yili Chuanning Bio's performance is expected to improve](https://longbridge.com/en/news/255391302.md)
*2025-09-01T03:03:02.000Z*
> KELUN PHARMA stated in an institutional research that the demand for the antibiotic sector is stabilizing. Despite price

### [Yili Chuanning Bio: In the first half of the year, the net profit attributable to the parent company was 455 million yuan, a year-on-year decrease of 40.64%](https://longbridge.com/en/news/254437244.md)
*2025-08-25T11:53:11.000Z*
> On August 25th, Yili Chuanning Bio disclosed its semi-annual report, stating that the company achieved operating revenue